Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Distributor Shanghai Pharmaceuticals Plans New Share Offering In Hong Kong

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - China's second-largest drug distributor plans to issue shares in Hong Kong in less than a year as it builds up its acquisitions war chest

You may also be interested in...



All Eyes On China As Market Activity Heats Up

Mergers and acquisitions in China’s life sciences industry are ramping up, with some segments, such as the orthopedic device space, particularly hot. As Chinese companies rise with the market, alliance deals are increasing sharply and financing deals remain stable, according to EBI’s Strategic Transactions database.

Shanghai Pharmaceutical Expands North; NDRC Price Cuts Impact M&A Targets

SHANGHAI - To accelerate its expansion and strengthen its presence in North China, Shanghai Pharmaceutical Holding Co. in January opened a new representative office in Beijing and established Beijing Shanghai Pharma Aixin Weiye Pharmaceutical Co., to be known as Weiye Pharma, while at the same time announcing the planned acquisition of China Health System

Shanghai Pharmaceutical Expands North; NDRC Price Cuts Impact M&A Targets

SHANGHAI - To accelerate its expansion and strengthen its presence in North China, Shanghai Pharmaceutical Holding Co. in January opened a new representative office in Beijing and established Beijing Shanghai Pharma Aixin Weiye Pharmaceutical Co., to be known as Weiye Pharma, while at the same time announcing the planned acquisition of China Health System

Related Content

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel